Article Figures & Data
Figures
- Figure 1
The management flow chart of patients with acute ischaemic stroke. CTA, CT angiography; CXR, chest X-ray; DBP, diastolic blood pressure; IV, intravenous; SBP, systolic blood pressure; TIA, transient ischaemic attack.
- Figure 2
Intravenous recombinant tissue plasminogen activator (IV rt-PA) administration in patients with ischaemic stroke within 4.5 hours of onset.
- Figure 3
Endovascular treatment in patients with acute ischaemic stroke (AIS). BP, blood pressure; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; rt-PA, recombinant tissue plasminogen activator.
- Figure 4
Antiplatelet treatment in patients with acute ischaemic stroke (AIS). INR, international normalised ratio; NOAC, novel oral anticoagulant. 1Non-disabling ischaemic cerebrovascular events refer to ischaemic cerebrovascular events without significant disability sequelae, including: 1. Transient ischemic attack (TIA) 2. Mild ischaemic stroke 3.Symptoms quickly relieved without significant disability sequelae. 2High-risk events include: 1. High-risk TIA (ABCD 2≥4 points) and mild stroke with 24h within onset. 2. Acute multiple cerebral infarction 3. Intracranial or extracranial aortic atherosclerotic stenosis ≥50%.
- Figure 5
Management of cerebral oedema/high intracranial pressure in patients with acute ischaemic stroke. BP, blood pressure; NICU, neurological intensive care unit.
- Figure 6
Haemorrhagic transformation management in patients with acute ischaemic stroke. INR, international normalised ratio.
- Figure 7
Epilepsy management within 24 hours after stroke onset.
- Figure 8
Diagnosis process for unexplained embolic stroke. CTA, CT angiography; ESUS, embolic stroke of undetermined source; MRA, magnetic resonance angiography.
- Figure 9
Blood pressure (BP) management in patients with acute ischaemic stroke (AIS).
- Figure 10
Blood pressure management in patients with acute ischaemic stroke. LDL-C, low-density lipoprotein-cholesterol; TIA, transient ischaemic attack; LOR B, Class IIB Recommendation .
Tables
- Table 1
Relative definitions of ischaemic cerebrovascular disease
Relative disease Definition Ischaemic cerebrovascular disease It refers to degeneration, necrosis or transient functional loss of local brain tissue, including nerve cells, glial cells and connective fibres, due to blood supply disorder. It is one of the common clinical diseases, which is often found in the middle-aged and elderly people, and has a high disability rate and mortality rate. Ischaemic stroke It refers to ischaemic necrosis or softening of local brain tissue caused by cerebral blood circulation disorder, ischaemia and hypoxia. Transient ischaemic attack (TIA) It refers to transient neurological dysfunction caused by focal ischaemia of brain, spinal cord or retina without acute cerebral infarction. Non-disabling ischaemic cerebrovascular events (NICE) It refers to ischaemic cerebrovascular diseases that do not leave neurological functional disability, including the following three groups of people: TIA, mild ischaemic stroke (NIHSS score ≤3 or ≤5), stroke that is rapidly relieved and does not leave disability. Its clinical features are usually mild symptoms or rapid and complete relief when the disease occurs, and no or only slight neurological deficits are left when the disease occurs, which does not affect daily life and work. Disabling ischaemic cerebrovascular events It refers to ischaemic cerebrovascular events with significant disability left after onset. Atherosclerotic cardiovascular diseases It refers to various clinical diseases with ischaemic or endothelial dysfunction-inflammatory changes caused by atherosclerosis, including acute coronary syndrome, myocardial infarction, stable or unstable angina pectoris, after coronary revascularisation, atherosclerosis-induced stroke or TIA (newly added), peripheral arterial disease or after vascular reconstruction. NIHSS, National Institutes of Health Stroke Scale.
Supplementary data
- Article
- Abstract
- Introduction
- Section 1: definitions associated with ischaemic cerebrovascular diseases
- Section 2: emergency assessment and diagnosis of patients with ischaemic stroke
- Section 3: reperfusion therapy for AIS
- Section 4: antiplatelet aggregation therapy for acute ischaemic cerebrovascular disease
- Section 5: other treatment in the acute phase
- Section 6: general supportive care and complications management
- Section 7: early evaluation and diagnosis of aetiology and pathogenesis of ischaemic cerebrovascular disease
- Section 8: intervention on aetiology and pathogenesis
- Section 9: management of risk factors and long-term intervention
- Footnotes
- References
- Figures & Data
- eLetters
- Info & Metrics